<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01652339</url>
  </required_header>
  <id_info>
    <org_study_id>HL-LDV-101</org_study_id>
    <nct_id>NCT01652339</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the pharmacokinetic characteristics of Lodivixx tab.5/160mg in healthy male&#xD;
      subjects&#xD;
&#xD;
        -  PK parameter evaluation&#xD;
&#xD;
        -  Safety profile evaluation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (maximum concentration)</measure>
    <time_frame>- Valsartan evaluation : 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48hr (14 points) - S-Amlodipine : 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 120, 168 (17 points)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(area under curve)</measure>
    <time_frame>- Valsartan evaluation : 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48hr (14 points) - S-Amlodipine : 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 120, 168 (17 points)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 3 days and follow-up period for maximum 6 days from the discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>Exforge tab. 10/160mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amlodipine besylate (10mg as amlodipine)&#xD;
valsartan 160mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lodivixx tab. 5/160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-amlodipine nicotinate (5mg as S-amlodipine)&#xD;
valsartan 160mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exforge tab. 10/160mg</intervention_name>
    <arm_group_label>Exforge tab. 10/160mg</arm_group_label>
    <other_name>- amlodipine besylate</other_name>
    <other_name>- valsartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lodivixx tab. 5/160mg</intervention_name>
    <arm_group_label>Lodivixx tab. 5/160mg</arm_group_label>
    <other_name>- S-amlodipine</other_name>
    <other_name>- valsartan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Years 20-45&#xD;
&#xD;
          -  Body weight ≥ 50kg and 18 ≤ BMI ≤ 29kg/m2&#xD;
&#xD;
          -  volunteer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with serious active cardiovascular, respiratory, hepatologic, renal,&#xD;
             hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological&#xD;
             disease or history of such disease&#xD;
&#xD;
          -  Subject with symptoms of acute disease within 28days prior to study medication dosing&#xD;
&#xD;
          -  Subject with known for history which affect on the absorption, distribution,&#xD;
             metabolism or excretion of drug&#xD;
&#xD;
          -  Subject with clinically significant active chronic disease&#xD;
&#xD;
          -  Subject with any of the following conditions in laboratory test i. AST(sGOT) or&#xD;
             ALT(sGPT) &gt; Upper normal limit × 1.5 ii. Total bilirubin &gt; Upper normal limit × 1.5&#xD;
             iii. renal failure with Creatinine clearance &lt; 50mL/min&#xD;
&#xD;
          -  Clinically significant hypotension when screening period (SBP &lt; 100mmHg, DBP &lt; 60mmHg)&#xD;
&#xD;
          -  Positive test results for HBs Ab, HCV Ab, Syphilis regain test&#xD;
&#xD;
          -  Use of any prescription medication within 14 days prior to study medication dosing&#xD;
&#xD;
          -  Use of any medication such as over-the-counter medication including oriental&#xD;
             medication within 7 days prior to study medication dosing&#xD;
&#xD;
          -  Subject with clinically significant allergic disease (except for mild allergic&#xD;
             rhinitis and mild allergic dermatitis that are not needed to administer drug)&#xD;
&#xD;
          -  Subject with known for hypersensitivity reaction to S-amlodipine, amlodipine and&#xD;
             valsartan and dihydropyridine derivatives&#xD;
&#xD;
          -  Subject who is not able to taking the institutional standard meal&#xD;
&#xD;
          -  Subjects with whole blood donation within 60days, component blood donation within&#xD;
             20days&#xD;
&#xD;
          -  Subjects receiving blood transfusion within 30days prior to study medication dosing&#xD;
&#xD;
          -  Participation in any clinical investigation within 60days prior to study medication&#xD;
             dosing&#xD;
&#xD;
          -  Continued excessive use of caffeine (caffeine &gt; five cups/day),&#xD;
             alcohol(alcohol&gt;30g/day) and severe heavy smoker (cigarette &gt; 10 cigarettes per day)&#xD;
&#xD;
          -  Subject who has been taken meal which affect on the absorption, distribution,&#xD;
             metabolism, excretion of drug, especially grapefruit juice&#xD;
&#xD;
          -  Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within&#xD;
             28days prior to study medication dosing&#xD;
&#xD;
          -  Continued serum potassium concentration abnormal status (on baseline visit, &lt; 3.5mEq/L&#xD;
             or &gt; 5.5mEq/L)&#xD;
&#xD;
          -  Subjects with decision of nonparticipation through investigator's review due to&#xD;
             laboratory test results or other excuse such as non-responding to request or&#xD;
             instruction by investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Gook Shin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Plosker GL, Robinson DM. Amlodipine/Valsartan: fixed-dose combination in hypertension. Drugs. 2008;68(3):373-81. Review.</citation>
    <PMID>18257612</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>July 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2012</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

